方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 脱发影响问卷（ALPPQ）× | Skindex-29（皮肤病生活质量指标）× | |
|---|---|---|
| 领域 | 皮肤病学 | 皮肤病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 2014 | 1997 |
| 提出者≠ | Gupta AK, Strober BE et al. | Chren MM, Lasek RJ |
| 类型 | Self-report | Self-report |
| 开创性文献≠ | Gupta AK, Talukder M. Alopecia areata: autoimmune basis of hair loss and available treatment options. Can J Dermatol. 2014;12(5):289-304. link ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| 别名 | Hair Loss Impact Questionnaire, Alopecia Areata QoL | Skindex, Skindex-QoL |
| 相关≠ | 4 | 1 |
| 摘要≠ | The Hair Loss Impact Questionnaire (Alopecia Areata Patient Priority Outcomes Questionnaire, ALPPQ) is a disease-specific, patient-administered quality-of-life measure assessing the psychosocial and functional burden of alopecia areata, a chronic autoimmune disorder causing patchy hair loss. Alopecia areata affects appearance, self-esteem, and social functioning disproportionately, often causing depression and anxiety. The ALPPQ captures these impacts, ensuring that treatment efficacy encompasses meaningful quality-of-life outcomes. It is increasingly used in clinical trials and observational studies of alopecia areata therapeutics. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGate数据集 ↗ |
|
|